XML 1070 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation Arrangements (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2012
Dec. 31, 2011
STOCK BASED COMPENSATION    
Schedule of stock based compensation expense

 

 

 

 

For the three months
ended September 30,

 

For the nine months
ended September 30,

 

 

 

2011

 

2012

 

2011

 

2012

 

 

 

($000s)

 

Research and development

 

39

 

16

 

130

 

49

 

General and administrative

 

171

 

59

 

515

 

202

 

Income (loss) from discontinued operations, net of tax

 

11

 

1

 

32

 

36

 

Stock-based compensation costs before income taxes

 

221

 

76

 

677

 

287

 

 

 

 

 

 

Year ended
December 31,
2009

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

 

 

$000

 

$000

 

$000

 

Research and development

 

271

 

351

 

171

 

Selling, general and administrative

 

484

 

1,344

 

669

 

Discontinued operations

 

55

 

51

 

42

 

Stock-based compensation costs before income taxes

 

810

 

1,746

 

882

 

Schedule of stock option activity

 

 

 

Options

 

Weighted
Average
Exercise 
Price

 

Weighted
Average
Remaining
Contractual
Term (years)

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

 

($000s)

 

 

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2011

 

502,253

 

$

26.11

 

6.44

 

140

 

Granted

 

33,571

 

$

3.29

 

 

 

 

 

Exercised

 

(15,438

)

$

3.06

 

 

 

 

 

Expired

 

 

 

 

 

 

 

Cancelled / forfeited

 

(39,970

)

$

20.03

 

 

 

 

 

Options outstanding at September 30, 2012

 

480,416

 

$

25.76

 

5.84

 

212

 

Unvested at September 30, 2012

 

77,607

 

$

9.00

 

8.67

 

36

 

Vested and exercisable at September 30, 2012

 

402,809

 

$

28.99

 

5.30

 

176

 

 

 

 

Cyclacel Pharmaceuticals, Inc.

 

Number of
options
outstanding

 

Weighted
average
exercise
price

 

Weighted
average
remaining
contractual
term (years)

 

Aggregate
intrinsic
value

 

Options outstanding at December 31, 2009

 

478,554

 

$

29.47

 

7.76

 

$

698

 

Granted

 

86,758

 

$

12.74

 

 

 

 

 

Exercised

 

(24,901

)

$

3.01

 

 

 

 

 

Cancelled/forfeited

 

(41,849

)

$

31.78

 

 

 

 

 

Options outstanding at December 31, 2010

 

498,562

 

$

27.72

 

7.22

 

$

938

 

Granted

 

28,500

 

$

10.64

 

 

 

 

 

Exercised

 

(948

)

$

2.87

 

 

 

 

 

Cancelled/forfeited

 

(23,865

)

$

40.53

 

 

 

 

 

Options outstanding at December 31, 2011

 

502,249

 

$

26.11

 

6.44

 

$

140

 

Unvested at December 31, 2011

 

90,237

 

$

12.11

 

8.75

 

$

3

 

Vested and exercisable at December 31, 2011

 

412,012

 

$

29.19

 

5.93

 

$

136

Schedule of information about options outstanding  

The following table summarizes information about options outstanding at December 31, 2011:

 

Exercise price ($)

 

Number
outstanding

 

Weighted
Average
remaining
contractual life

 

Number
exercisable

 

2.03 — 13.86

 

217,130

 

7.77

 

144,770

 

15.05 — 34.65

 

53,983

 

7.15

 

36,713

 

36.82 — 40.67

 

72,602

 

5.82

 

71,996

 

44.10 — 48.65

 

127,320

 

4.57

 

127,319

 

54.60 — 105.00

 

31,214

 

4.93

 

31,214

 

 

 

502,249

 

 

 

412,012

 

 

Schedule of assumptions for stock option grants to employees and directors

 

 

 

For the nine months
ended September 30,

 

 

 

2011

 

2012

 

Expected term

 

5 — 6 yrs.

 

6 yrs.

 

Risk free interest rate

 

1.47 — 2.29%

 

0.95%

 

Expected volatility

 

93 — 99%

 

98%

 

Expected dividend yield over expected term

 

 

 

Resulting weighted average grant fair value

 

$8.05

 

$2.52

 

 

 

 

 

Year ended
December 31,
2009

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

Expected term (years)

 

0.75 — 5 Yrs

 

5 — 6 Yrs

 

5 — 6 Yrs

 

Risk free interest rate

 

0.325 — .84%

 

1.64 — 2.96%

 

1.47 — 2.29%

 

Volatility

 

65 — 169%

 

90 — 102%

 

93 — 99%

 

Dividends

 

0.00%

 

0.00%

 

0.00%

 

Resulting weighted average grant date fair value

 

$2.73

 

$9.80

 

$8.05

 

 

Schedule of restricted stock activity

 

 

 

Restricted Stock

 

Weighted Average Grant
Date Value Per Share

 

Non-vested at December 31, 2011

 

1,632

 

$

3.08

 

Vested

 

(1,341

)

$

3.08

 

Non-vested at September 30, 2012

 

291

 

$

3.08

 

 

 

 

 

Restricted Stock

 

Weighted Average Grant
Date Value Per Share

 

Non-vested at December 31, 2009

 

5,204

 

$

3.08

 

Vested

 

(1,786

)

$

3.08

 

Non-vested at December 31, 2010

 

3,418

 

$

3.08

 

Vested

 

(1,786

)

$

3.08

 

Non-vested at December 31, 2011

 

1,632

 

$

3.08

Schedule of restricted stock units activity

 

 

 

Restricted Stock Units

 

Weighted Average Grant
Date Value Per Share

 

Non-vested at December 31, 2011

 

36,463

 

$

5.60

 

Granted

 

12,281

 

$

3.85

 

Forfeited

 

(6,904

)

$

4.99

 

Vested

 

(2,010

)

$

3.08

 

Non-vested at September 30, 2012

 

39,830

 

$

5.32

 

 

 

 

 

 

Restricted Stock Units

 

Weighted Average Grant
Date Value Per Share

 

Non-vested at December 31, 2009

 

7,812

 

$

3.08

 

Vested

 

(2,670

)

$

3.08

 

Non-vested at December 31, 2010

 

5,142

 

$

3.08

 

Granted

 

34,000

 

$

5.81

 

Vested

 

(2,679

)

$

3.08

 

Non-vested at December 31, 2011

 

36,463

 

$

5.60